User:Mr. Ibrahem/Tisotumab vedotin

Tisotumab vedotin, sold under the brand name Tivdak, is a medication used to treat cervical cancer. It is used when other treatments are not effective. It is given by gradual injection into a vein every 3 weeks.

Common side effects include tiredness, nausea, peripheral neuropathy, hair loss, nose bleeds, kidney problems, eye problems, diarrhea, and rash. Other side effects may include pneumonitis. Use in pregnancy may harm the baby. It is an antibody-drug conjugate, a combination of tisotumab, a monoclonal antibody against tissue factor, and monomethyl auristatin E (MMAE), an inhibitor of cell division.

Tisotumab vedotin was approved for medical use in the United States in 2021. As of 2022 it is not approved in Europe or the United Kingdom. In the United States a dose of 120 mg costs about 19,300 USD as of 2022.